KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer

KRAS mutation is a major driver of pancreatic carcinogenesis and will likely be a therapeutic target. Due to lack of sensitive assays for clinical samples of pancreatic cancer with low cellularity, KRAS mutations and their prognostic association have not been fully examined in large populations. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Tatsunori, Masugi, Yohei, Inoue, Yosuke, Hamada, Tsuyoshi, Tanaka, Mariko, Takamatsu, Manabu, Arita, Junichi, Kato, Tomotaka, Kawaguchi, Yoshikuni, Kunita, Akiko, Nakai, Yousuke, Nakano, Yutaka, Ono, Yoshihiro, Sasahira, Naoki, Takeda, Tsuyoshi, Tateishi, Keisuke, Uemura, Sho, Koike, Kazuhiko, Ushiku, Tetsuo, Takeuchi, Kengo, Sakamoto, Michiie, Hasegawa, Kiyoshi, Kitago, Minoru, Takahashi, Yu, Fujishiro, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459293/
https://www.ncbi.nlm.nih.gov/pubmed/35567350
http://dx.doi.org/10.1111/cas.15398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459293/
https://www.ncbi.nlm.nih.gov/pubmed/35567350
http://dx.doi.org/10.1111/cas.15398

Ejemplares similares